BPD-102US

Appln. No.: 10/563,659

Amendment Dated: March 5, 2010

Reply to Final Office Action of December 7, 2009

Amendments to the Claims: This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently Amended) A device for the simultaneous and qualitative or quantitative determination of a plurality of blood group antigens in a blood sample, the device comprising consisting essentially of:

a single membrane having an application zone for the application of the blood sample, at least one group of at least two indicator zones, each indicator zone comprising a bonding element which is able to bind to the blood group antigen to be tested for, and at least one absorption region which takes up the blood after the blood passes through the group of indicator zones, wherein the indicator zones are located between the application zone and the at least one absorption region and are positioned on the membrane substantially parallel to each other and absent a liquid barrier between indicator zones, and wherein the blood group antigen bound to the bonding element is immobilized within the indicator zone.

- 2. (Canceled)
- 3. (Previously Presented) The device according to claim 1, wherein the indicator zones are arranged in a W-, M-, or N-shape or a linear row.
- 4. (Previously Presented) The device according to claim 1, wherein the bonding elements comprise antibodies, lectines, or fragments thereof.
- 5. (Previously Presented) The device according to claim 4, wherein the antibodies or fragments thereof specifically bind to a blood group antigen selected from the group consisting of A, B, AB, D, C, c, E, e, Cw, and K.
- 6. (Previously Presented) The device according to claim 1, wherein the membrane consists of polyethylene, nitrocellulose or nylon.
- 7. (Previously Presented) The device according to claim 1, wherein downstream of the application zone and upstream of the indicator zones at least one sealing element is provided on the membrane.

Appln. No.: 10/563,659 BPD-102US

Amendment Dated: March 5, 2010

Reply to Final Office Action of December 7, 2009

8. (Previously Presented) The device according to claim 1, wherein the device is positioned onto a support layer.

9. (Previously Presented) The device according to claim 1, wherein the device is integrated in a casing.

10.-19. (Canceled)

20. (Currently Amended) A device for the simultaneous and qualitative or quantitative determination of a plurality of blood group antigens in a blood sample, the device comprising consisting essentially of:

a single membrane having an application zone for the application of the blood sample, at least one group of at least two indicator zones, each indicator zone comprising a bonding element which is able to bind to the blood group antigen to be tested for, and at least one absorption region which takes up the blood after the blood passes through the group of indicator zones, wherein the indicator zones are located between the application zone and the at least one absorption region and are positioned on the membrane diagonal to each other and absent a liquid barrier between indicator zones, and wherein the blood group antigen bound to the bonding element is immobilized within the indicator zone.

- 21. (Previously Presented) The device according to claim 20, wherein the indicator zones are arranged in a diagonal V-, W-, M-, or N-shape.
- 22. (Previously Presented) The device according to claim 1, comprising at least two groups of indicator zones and at least two absorption regions, wherein the application zone is positioned in the central region of the membrane.
- 23. (Previously Presented) The device according to claim 20, comprising at least two groups of indicator zones and at least two absorption regions, wherein the application zone is positioned in the central region of the membrane.
- 24. (Previously Presented) The device according to claim 1, further comprising an indicator zone comprising a control bonding element which indicates the flow of the blood sample through the indicator zones, wherein the control bonding element is an anti-erythrocyte antibody.

BPD-102US

Appln. No.: 10/563,659

Amendment Dated: March 5, 2010

Reply to Final Office Action of December 7, 2009

25. (Previously Presented) The device according to claim 20, further comprising an indicator zone comprising a control bonding element which indicates the flow of the blood sample through the indicator zones, wherein the control bonding element is an anti-erythrocyte antibody.

26. (Currently Amended) A device for the simultaneous and qualitative or quantitative determination of a plurality of blood group antigens in a blood sample, the device comprising consisting essentially of:

a single membrane having an application zone for the application of the blood sample, at least two groups of at least two indicator zones, each indicator zone comprising a bonding element, which is able to bind to the blood group antigen to be tested for, and at least two absorption regions which takes up the blood after the blood passes through the group of indicator zones, wherein the application zone is positioned in a central region of the membrane, the indicator zones are located between the application zone and the at least one absorption region and are positioned on the membrane substantially parallel to each other and absent a liquid barrier between indicator zones, and wherein the blood group antigen bound to the bonding element is immobilized within the indicator zone.

27. (New) A device for the simultaneous and qualitative or quantitative determination of a plurality of blood group antigens in a blood sample, the device consisting of:

a single membrane having an application zone for the application of the blood sample, at least one group of at least two indicator zones, each indicator zone comprising a bonding element which is able to bind to the blood group antigen to be tested for, and at least one absorption region which takes up the blood after the blood passes through the group of indicator zones, wherein the indicator zones are located between the application zone and the at least one absorption region and are positioned on the membrane substantially parallel to each other and absent a liquid barrier between indicator zones, and wherein the blood group antigen bound to the bonding element is immobilized within the indicator zone.